IL17A and inflammatory bowel disease: The therapeutic targeting of individual cytokines of the so-called IL-23/IL-17 axis has proved efficacious in several immune-mediated inflammatory diseases (IMIDs), including PsO, PsA, axSpA, inflammatory bowel disease (IBD), and HS.